Movement Disorders

Laxman Bahroo, DO, examines the effectiveness of on-demand therapies to manage OFF episodes in Parkinson disease and highlights the importance of frequent monitoring and follow-up visits.

Rajesh Pahwa, MD, comments on the different routes of administration of on-demand therapies and medication absorption for the management of OFF episodes in Parkinson disease.

Through the StrivePD ecosystem and an Apple Watch, patients, including those who have been treated with Medtronics’ deep brain stimulation device, are able to track and log their symptoms.

After a protocol adjustment that disallowed the use of the antiemetic trimethobenzamide during dose-titration, adverse event data from an open-label study of apomorphine sublingual film (Kynmobi; Sunovion) suggest antinausea treatment might not be necessary.

The pharmacodynamic and pharmacokinetic effects of the novel Amneal Pharmaceuticals therapy suggest that it can overcome the current absorption and exposure limitations of the oral levodopa therapies used to treat those with Parkinson disease motor fluctuations.

Here's what is coming soon to NeurologyLive®.

The semi-retired neurologist and consultant with the PMD Alliance offered her takeaways from the 2022 ATMRD Congress in Washington, DC, and her advice for younger clinicians getting into the field. [WATCH TIME: 3 minutes]

In a presentation at the 2022 ATMRD Congress, Rajesh Pahwa, MD, FANA, FAAN, spoke about the hope held for stem cell approaches and the potential to improve care with several therapies with possible approvals on the horizon.

Despite a less than favorable view of the pharmaceutical industry among the general population, there are still benefits to the work being done by clinicians who transition to this line of work according to the semi-retired neurologist and consultant with the PMD Alliance. [WATCH TIME: 2 minutes]

Data from a PMD Alliance survey of more than 700 individuals with PD or their care partners showed significant associations between decreased social support and exasperation of nonmotor and cognitive symptoms of PD.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement and related disorders.

A survey of more than 4000 individuals with PD and their caregivers suggests that almost 90% would be willing to use subcutaneous injectable therapies to control their disease, contrasting the current anecdotal belief of “needle phobia” in this population.

The study, expected to be completed in 2024, will look specifically at vocal abnormalities related to the early stages of Parkinson disease progression.

The semi-retired neurologist and consultant with the PMD Alliance discussed the importance of the patient care team and having multiple specialists and disciplines included in that process. [WATCH TIME: 2 minutes]

In a presentation at the 2022 ATMRD Congress, Jill Farmer, DO, MPH, outlined several novel options for the treatment of OFF episodes in Parkinson disease, and stressed the need for individualized approaches to maximize patient quality of life.

In a first, but indirect, comparison of the 3 available formulations of amantadine for the treatment of Parkinson disease, only the delayed-release/extended-release formulation (Gocovri) resulted in improvements in both in OFF time and dyskinesia.

The semi-retired neurologist and consultant with the PMD Alliance shared her perspective on the progress that has been made in therapeutics for the treatment of movement disorders, and the role of social prescribing for these patients. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 17, 2022.

The investigators noted that the data on tolerability and efficacy support that treatment with opicapone among older adults with PD requires no age-related dose adjustments.

Robert A. Hauser, MD, MBA, and Laxman Bahroo, DO, review unmet needs in managing OFF episodes for patients with Parkinson Disease.

Rajesh Pahwa, MD, provides insight on initiating treatment after the manifestation of OFF episodes and reviews current treatment options for Parkinson disease.

Drs Robert A. Hauser, Rajesh Pahwa, and Laxman Bahroo discuss factors to consider when approaching treatment selection for managing OFF episodes in Parkinson Disease.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Headache Society.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 10, 2022.

Experts in movement disorders share the importance of multidisciplinary team collaboration for the management of OFF episodes and shared-decision making for treating Parkinson disease.

Robert A. Hauser, MD, MBA, and Rajesh Pahwa, MD, comment on therapeutic obstacles in treating OFF episodes and how to optimize the management of patients with Parkinson disease.

Rajesh Pahwa, MD, leads a discussion on approaching conversations about ON and OFF episodes in Parkinson disease throughout a patient’s treatment journey.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.